Physician profile
Heidi T Orme
NPI 1922201615
$1,913.24
in general payments reported to CMS, 2019-2025
15 companies · $458 in 2025
The $458 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.74 · 2020: $115 · 2021: $287 · 2022: $448 · 2023: $275 · 2024: $277 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $861 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $860.69 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $618.39 | 2020-2025 | Zeposia |
| Abbvie INC. | $346.23 | 2021-2025 | |
| Biogen, INC. | $232.60 | 2021-2025 | Tysabri, Vumerity |
| Ucb, INC. | $146.64 | 2020-2025 | Fintepla |
| Genentech USA, INC. | $115.63 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Lilly USA, LLC | $98.86 | 2020-2025 | Kisunla, Emgality, Reyvow |
| Argenx US, INC. | $97.48 | 2022 | |
| Novartis Pharmaceuticals Corporation | $65.49 | 2019-2022 | |
| Lundbeck LLC | $58.77 | 2022 | |
| Tanabe Pharma America, INC. | $32.99 | 2023-2024 | |
| Axsome Therapeutics, INC. | $26.65 | 2025 | Symbravo |
| C2n Diagnostics, LLC | $22.87 | 2025 | Precivityad2 |
| Abbott Laboratories | $20.47 | 2021 | |
| Edw Pharma, INC. | $16.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Orme listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.